Vita Life SciencesASX:VLS -2.00%85 PEG Ratio is 1.56 as of Jun. 26, 2026, which is 111% above its 10-year median of 0.74. GuruFocus rates ASX:VLS with a GF Score™ of 85/100 and a GF Value™ of A$2.48 (Fairly Valued). The stock has 1 warning sign investors should review. Among 347 Drug Manufacturers companies, Vita Life Sciences ranks better than 51.3% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Vita Life Sciences's PEG Ratio or its related term are showing as below:
ASX:VLS'
s PEG Ratio Range Over the Past 10 Years
Min: 0.42 Med: 0.74 Max: 3.46
Current: 1.56
During the past 13 years, Vita Life Sciences's highest PEG Ratio was 3.46. The lowest was 0.42. And the median was 0.74.
ASX:VLS's PEG Ratio is ranked better than 51.3% of 347
companies
in the Drug Manufacturers industry
Industry Median: 1.71
vs ASX:VLS: 1.56
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Vita Life Sciences (ASX:VLS) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Vita Life Sciences PEG Ratio Related Terms
Vita Life Sciences PEG Ratio Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Vita Life Sciences (ASX:VLS) has a PEG Ratio of 1.56 as of Jun. 26, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Vita Life Sciences and its competitors. This is 111% above median its historical median of 0.74. Over the past decade, Vita Life Sciences' PEG Ratio has ranged from 0.42 to 3.46. According to the industry distribution chart, Vita Life Sciences ranks #169 out of 347 companies in the Drug Manufacturers industry, placing it in the top 48.7%.
Is Vita Life Sciences' PEG Ratio too high?
Vita Life Sciences' current PEG Ratio of 1.56 is 111% above median its 10-year median of 0.74. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 3.46. The Drug Manufacturers industry median PEG Ratio is 1.71. Vita Life Sciences' value of 1.56 is 8.8% below this industry median. Based on the distribution chart, Vita Life Sciences ranks #169 out of 347 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' PEG Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #169 out of 347 companies for PEG Ratio. This puts Vita Life Sciences in the upper half of its industry. The industry median PEG Ratio is 1.71. Vita Life Sciences' value of 1.56 is 8.8% below this benchmark. Historically, Vita Life Sciences' own PEG Ratio has ranged from 0.42 to 3.46 over the past decade. While the company's 10-year median is 0.74 vs. the industry median of 1.71, Vita Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.71, based on 347 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current PEG Ratio of 1.56 is 8.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current PEG Ratio is 1.56, which is 111% above median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.48, compared to a current price of A$2.45 — trading 1.2% below its estimated fair value. The current PEG Ratio is 1.56, which is 111% above median its 10-year median of 0.74 and 8.8% below the Drug Manufacturers industry median of 1.71. Vita Life Sciences' overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current PEG Ratio is 1.56 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be undervalued.
The current stock price of A$2.45 is trading 1.2% below its estimated GF Value™ of A$2.48.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
PEG Ratio: 1.56 (111% above median its 10-year median of 0.74)
GF Value™: A$2.48 vs. price of A$2.45 (1.2% below fair value)
Industry Position: 8.8% below the Drug Manufacturers median (#169 of 347)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
85GF Score
Get the complete analysis for ASX:VLS
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
